Windtree Therapeutics, Inc. · OTC:WINT

Windtree Therapeutics — Discovery Laboratories — Corporate Update (October 2012)

18 slides from Windtree Therapeutics's corporate update, Oct 24, 2012

  1. Slide 1: SURFAXIN & AFECTAIR US Commercialization Update

    * October 2012 NASDAQ: DSCO SURFAXIN® & AFECTAIR® US Commercialization Update

  2. Slide 2: Forward Looking Statement

    * Forward Looking Statement To the extent that statements in this presentation are not strictly historical, including statements about the Company's business strategy, outlook, objectives, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Comp

  3. Slide 3: Teleconference Overview

    * Teleconference Overview Introduction – Significant opportunity in Neonatal Critical CareUS Neonatology Market PreparationSURFAXIN® US Product LaunchAFECTAIR® US Product LaunchAEROSURF® UpdateFinancial / Strategic ConsiderationsQ&A

  4. Slide 4: DSCO: Improving The Standard of Respiratory Critical Care

    * DSCO: Improving The Standard of Respiratory Critical Care KL4 surfactant technology – a synthetic, peptide-containing surfactant that is structurally similar to human pulmonary surfactant Aerosolized drug delivery technologies to improve delivery of therapies to critical care patients A specialty

  5. Slide 5: Initial Focus: Respiratory Distress Syndrome (RDS) in Premature Infants

    * Initial Focus: Respiratory Distress Syndrome (RDS) in Premature Infants KL4 surfactant portfolio has the potential to greatly improve the management of RDS and, over time, expand the current RDS estimated worldwide annual market of $200 million to a $1 billion market opportunity Estimates based on

  6. Slide 6: DSCO Near-term Priorities

    * DSCO Near-term Priorities SURFAXIN® is the first FDA approved (March 2012) synthetic, peptide-containing surfactant for use in RDS and the only alternative to animal-derived surfactants in the U.S. AFECTAIR® was cleared for marketing in the U.S. by the FDA in Feb. 20121. Launch SURFAXIN and AFECTA

  7. Slide 7: Priority – Preparing the Market for SURFAXIN and AFECTAIR

    * Priority 1 – Preparing the Market for SURFAXIN® and AFECTAIR® Commercial and medical affairs field teams in placeExtensive experience in respiratory critical care / hospital setting, including pharmaceuticals and medical devicesNational Launch Meeting Held in OctoberShort term goals:National accou

  8. Slide 8: Priority – Cont'd SURFAXIN Product Availability

    * Priority 1 – Cont'd SURFAXIN® Product Availability Technical team leadership has been focused on business supply continuityManufacturing: Discovery Labs has been manufacturing at a commercial scale for several years.Supply Chain: Warehouse & specialty distributor agreements are in placeQuality con

  9. Slide 9: Preparing the Market for SURFAXIN

    * Preparing the Market for SURFAXIN® Neonatologists (A)(n=105) Pharmacy Directors (B)(n=51) Data on file, Discovery Laboratories, Inc. 2012* Baseline assessment prior to customer interaction with DSCO field team Very/ Likely to Advocate Surfaxin Recent Market Survey: High Interest in SURFAXIN® Favor

  10. Slide 10: SURFAXIN NICU Market Economics & Pricing

    * SURFAXIN® NICU Market Economics & Pricing Uncomplicated U.S. reimbursement under DRGFederal Supply Schedule (FSS) agreement submitted – limited impact on businessUse of pharmacoeconomic data is expected to redefine the value proposition for surfactant replacement therapySURFAXIN® reintubation data

  11. Slide 11: SURFAXIN Commercial Strategy & Revenue Potential

    * SURFAXIN® Commercial Strategy & Revenue Potential Launched U.S. FieldTeam---Extensive Respiratory and Neonatal Experience 1st Full Year Revenues $8M - $10M Growth Phase: Significant Adoption in US Neonatal Centers---Compelling HECON Data Full Year 4 Revenues $40M - $50M Goal: U.S. Standard of Care

  12. Slide 12: AFECTAIR US Commercial Launch on Track

    * AFECTAIR® US Commercial Launch on Track AFECTAIR® strategy: create a new market based on unmet need associated with challenges of aerosol delivery todayLaunching initial device for use in infants requiring ventilatory support in the NICU/PICUApproximately 355K NICU/PICU eligible patients in US eac

  13. Slide 13: AFECTAIR US Commercial Launch on Track: User Experience Program

    * AFECTAIR® US Commercial Launch on Track Key launch tactic: user experience programFinal pricing to be determined through feedback from user experience program Expect to stock warehouse with AFECTAIR® commercial product in December 2012Management believes revenue potential for the initial device is

  14. Slide 14: RDS: Significant Patient Population Underserved by Animal-Derived Surfactants

    * Infants at high risk receive animal-derived surfactant and invasive mechanical ventilation as first or second line therapy Infants with moderate risk receive nCPAP as first line therapy (no surfactant)Approximately 30% to 40% failure rate RDS: Significant patient population underserved by undiffer

  15. Slide 15: Priority 2: Initiate AEROSURF P2 Clinical Program

    * Priority 2: Initiate AEROSURF® P2 Clinical Program AEROSURF® Architecture & Key initiatives:Lyophilized KL4 Surfactant: process tech transfer to CMO underway; Target to complete commercial scale process validation by mid-2013Capillary Aerosol Generator: Contracted with 3rd party expert team; targe

  16. Slide 16: Priority 3: International Strategic Partnership for RDS

    * Desirable Partner Characteristics:Invests in innovative, specialty opportunities, i.e. – pediatric respiratory critical careHas strong hospital commercial presence – focus on EU and potentially other major marketsFinancial strengthViews our product(s) as important part of its portfolio – AEROSURF®

  17. Slide 17: KL4 Surfactant Portfolio: Potential to Transform RDS

    * KL4 Surfactant Portfolio: Potential to Transform RDS Synthetic KL4 Surfactant Lyophilized KL4 Surfactant Potential to improve safety, simplify drug administration, optimize handling & shelf-life Preparing for phase 3 program Goal: Global line extension of SURFAXINPotential Revenues: $250M Aerosoli

  18. Slide 18: Q&A

    Q&A DiscoveryLabs.)

Discovery Laboratories — Corporate Update (October 2012) on 6ix